• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

DNDi mourns passing of Guy Mazué

Respected toxicologist was a long-time colleague and friend to DNDi

21 Feb 2020

DNDi has learned, with great sadness, that long-time colleague and friend Guy Mazué has passed away. Guy worked closely with DNDi from its founding in 2003 and even before, advising the working group that created DNDi. He was involved in much of the organization’s toxicology work for many years, including on pre-clinical and clinical drug candidates for malaria, sleeping sickness, and leishmaniasis.

“He was a wise person, larger than life, and a friend and mentor to several of us within the DNDi team,” said Dr Bernard Pécoul, Executive Director, DNDi. “Guy worked with us as a consultant from the beginning; it was a privilege to count on his collaboration and expertise.”

“For me, he was like a mentor, a guide. I learned a lot with him,” said Stéphanie Braillard, Non-Clinical Development Senior Manager, DNDi. “He was very generous, and especially generous with the help he provided. If I had any questions regarding a molecule, a safety concern, a strategy to move ahead, I could ask him at any time.”

As an expert toxicologist, Guy worked in senior posts at Sanofi and, later, Pharmacia and Upjohn, where he was Vice President, Deputy Worldwide Toxicology. He was also an expert and member of several working groups of the French drug regulatory agency, Agence Nationale de Sécurité du Médicament et des Produits de Santé.

“He had a lot of patience to share, explain, and teach, and he had a great sense of humour and a lot of humility,” noted Dr Robert Don, Discovery & Pre-Clinical Director at DNDi from 2005 to 2017. “The whole drug discovery group would turn to Guy for explanations. He really taught people toxicology.”

After his retirement, Guy continued to work as a consultant, including with DNDi, most recently helping the team to successfully bring leishmaniasis drug candidates DNDI-0690 and DNDI-6148 to first-in-human clinical trials. Even after he stopped working as a consultant, he continued to answer questions from the Discovery and Translation teams.

Guy was also a keen winemaker and connoisseur, a great cook, and an organizer of wonderful parties.

“He had a great laugh, and also these big workers’ hands, not the hands you might expect of someone who worked in offices and labs! Big calloused hands from working outside in the field. He produced wine from his own grapes,” remembered Dr Isabela Ribeiro, Head, Dynamic Portfolio Unit, DNDi, who first met Guy in the 1990s when they both worked at Pharmacia.

“When I retired from DNDi, his farewell gift to me was a lovely bottle of his own eau de vie,” said Robert.

“I will definitely think of Guy when I finish my own bottles of Mirabelle and Poire William. This might take a few years!” added Stéphanie.

Guy would have celebrated his 76th birthday last week.

Read, watch, share

Loading...
Mamadou Diop senior health technician - biologist at CERPAD Lab at Gaston Berger University
Stories
17 Jun 2026

The DNDi-MMV Joint Regulatory Platform: ‘a pioneering programme project for non-profit medical research organizations to speak with one voice’

MASAMUNA, DR CONGO, JANUARY 2026: The mother superior of the nuns who run the local clinic is also the lab technican.
Press releases
12 Jun 2026

DRC approves the use of acoziborole, a breakthrough one-day oral treatment against sleeping sickness 

Statements
9 Jun 2026

DNDi Statement at the UN Multi-Stakeholder Hearing on Pandemic Prevention, Preparedness, and Response (PPPR)

Press releases
8 Jun 2026

DNDi, GARDP, and MMV join forces to accelerate drug development for patients in greatest need

Statements
19 May 2026

DNDi interventions at the 79th World Health Assembly

Dr Sergio Sosa-Estani
Statements
15 May 2026

DNDi statement on hantavirus outbreak: ‘Investment in pandemic preparedness efforts remains insufficient.’

Statements
13 May 2026

DNDi’s briefing note for 79th World Health Assembly

Close up of legs with sandals on a dry soil
Press releases
12 May 2026

DNDi welcomes GHIT support for global evaluation and registration of fosravuconazole for eumycetoma, in collaboration with Eisai

VIEW ALL

Help neglected patients

To date, we have delivered fourteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Youtube X-twitter Tiktok Facebook-f
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license